Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05627323 · ClinicalTrials.gov registry record · Phase 1
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
A Phase 1 study of Glioblastoma Multiforme of Brain, sponsored by Chimeric Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT05627323: Active Phase 1 study of Glioblastoma Multiforme of Brain, sponsored by Chimeric Therapeutics.
NCT05627323 is a Phase 1 study of Glioblastoma Multiforme of Brain that is active but no longer recruiting, run by Chimeric Therapeutics. The registered enrollment target is 42 participants, below the 155-participant average among 11 other Glioblastoma Multiforme of Brain trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05627323, a Phase 1 study of Glioblastoma Multiforme of Brain, is active but no longer recruiting, sponsored by Chimeric Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the effectiveness of CHM-1101 in treating MMP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive).
Primary Outcome
Assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
Conditions Studied
Interventions
- BIOLOGICAL CHM-1101 CAR-T cells
Study Locations (2)
California
- City of Hope Medical Center - Duarte
Texas
- St. David's South Austin Medical Center - Sarah Cannon - Austin - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2041-01 |
| Phase | Phase 1 |
What the registry record for NCT05627323 still lists
NCT05627323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 155-participant average among 11 other Glioblastoma Multiforme of Brain trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Glioblastoma Multiforme of Brain appearing as the primary indexed condition, and to 1 intervention - of which CHM-1101 CAR-T cells is the first listed.
NCT05627323 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT05627323 about?
NCT05627323 is a clinical study titled "CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma". This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the effectiveness of CHM-1101 in treating MMP2+ glioblastoma that has come ba...
What is the current status of trial NCT05627323?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-06-06. Estimated completion is 2041-01.
What conditions does trial NCT05627323 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme of Brain.
What interventions are being tested in trial NCT05627323?
The interventions under investigation include: CHM-1101 CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05627323?
This trial is sponsored by Chimeric Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05627323 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme of Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05627323's enrollment target sits among peer trials
42 6th of 11 higher than 5 of 11 other Glioblastoma Multiforme of Brain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme of Brain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
RECRUITING · Phase 1
-
Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®
RECRUITING · Phase 1
-
Trial of C134 in Patients With Recurrent GBM
ACTIVE NOT RECRUITING · Phase 1
-
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
RECRUITING
-
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
RECRUITING
-
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI